Changes in choroidal thickness after ranibizumab and aflibercept Therapy for treatment‐naïve wet age‐related macular degeneration

Abstract

PurposeTo compare the changes in subfoveal choroidal thickness between ranibizumab and aflibercept therapy for treatment‐naive wet age‐ related macular degeneration.MethodsThis retrospective, observational study included 47 eyes of treatment‐naive wet age‐related macular degeneration patients who were followed up for at least 6 months after initial injection. All eyes were treated with 3 consecutive monthly injection of ranibizumab or aflibercpt, and treated with PRN injection of anti‐vascular endothelial growth factor after 3 consecutive monthly injection. Subfoval choroidal thickness was measured using enhanced depth imaging optical chorence tomography.ResultsIn the ranibizumab injected group (25 eyes), mean changes in choroidal thickness was −9.80, −16.86, −25.08, −10.40 μm at 1, 2, 3, 6 months after initial injection respectively. In the aflibercept injection group (22 eyes), mean changes in choroidal thickness was −24.30, −32.73, −37. 52, −15.77 μm at 1, 2, 3, 6 months after initial injection respectively. The mean changes in subfoveal choroidal thickness was significantly greater in the aflibercept injected group (p < 0.05) at 1 month, but there was no significant difference between two group at 2, 3, and 6 months after initial injection (p > 0.05).ConclusionsSubfoveal choroidal thickness was decreased after ranibizumab and aflibercept therapy. The mean changes in subfoveal choroidal thickenss was greater in aflibercept injected group at 1 month, but there was no significant difference between two therapy at 2, 3, and 6 months after initial injection.